Automated Flow Cytometry Enables Standardized, Rapid Profiling of Cellular Starting Material for Predictable, Potent Products
CYTO 2026 | June 6-10 | West Palm Beach, USA
Description: The Accellix Platform harmonizes results across operators and sites, providing a meaningful step forward in the standardization of flow cytometry, and linking starting material assessment with predictable, potent cell therapy products.
Poster highlights:
- Characterization of starting material is now seen as integral for ensuring downstream product quality.
- Cell therapy drug potency is sensitive to the quality and composition of the starting material, including heterogeneity in cell subset frequency and functional state, and sample handling conditions during collection, transportation, and storage.
- Understanding the cellular attributes of starting material allows manufacturers to establish appropriate potency metrics and predict final product quality.
Provide the following information and we’ll email you a copy of the poster:
*Required field
